Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, has announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock, at a public offering price of US$215 per share, before underwriting discounts and commissions. In addition, Inspire has granted the underwriter a 30-day option to purchase up to an additional 150,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover sales by the underwriter in the initial offering of the shares or in the open market. All of the shares in the offering are to be sold by Inspire. The offering is expected to close on August 16, 2022, subject to customary closing conditions.
Latham & Watkins LLP represents Inspire in the offering with a corporate deal team led by New York partner Nathan Ajiashvili, Orange County partner Shayne Kennedy, and New York counsel Lindsey Mills, with associates Paul Rafla and Matthew Schlanger.